NEXGEL INC (NXGL)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$0.32-6.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
NexGel acquired an exclusive license to grow its biomaterials business. The company raised $1.21 million in capital in 2026-Q1. Analysts expect revenue to grow about 18% next year. The new CFO appointment may improve financial management.
NexGel is still losing money and faces Nasdaq listing risks. The company’s revenue and earnings estimates have recently been cut. Key officers resigned, showing management instability. The stock price has fallen 27% from its high.
The market expects about 18% revenue growth next year. Our fair value is near $3.71, reflecting these expectations. The stock trades about 85% below consensus price, signaling high risk.
Breaks if: Capital raised falls below $1.21 million in 2026-Q1
Breaks if: Nasdaq deficiency unresolved or key management resignations continue
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
NXGL represents a speculative growth investment with a focus on integrating new acquisitions. The current thesis is cautious due to recent earnings misses and management volatility.
The market seems to price in a low expectations gap, suggesting that NXGL is viewed as cheap compared to its peers. However, the overall valuation reflects concerns about its loss-making status and recent performance.
Fundamentals are likely to remain weak in the near term, given the high probability of an earnings miss. Management is focused on integration and compliance, but execution risks are elevated.
The thesis hinges on management's ability to successfully integrate the Celularity portfolio and address Nasdaq compliance issues. Additionally, sector performance from bellwethers could influence NXGL's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company missed earnings expectations, raising concerns about capital raising efforts. This miss adds pressure to its financial stability and outlook. The overall market has also shown a risk-off sentiment, which may further impact NXGL.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Resolve Nasdaq listing deficiency due to stock price below $1.00 by seeking shareholder approval for authorized shares increase and reverse stock split.
Newly stated in 2026-Q2. Management disclosed receipt of Nasdaq deficiency letter due to stock price below $1.00 and plans to seek shareholder approval for share increase and reverse split to regain compliance. No financial metrics directly quantify progress yet; this is a regulatory compliance priority with active management focus.
“The Company intends to resolicit shareholder approval for the increase in authorized shares and reverse split authority as standalone proposals, without the redomicile component.”
Breaks if: YoY revenue growth falls below 17.6% in FY26
Acquire an exclusive license to Celularity's biomaterials portfolio.
In the next 1 to 3 years, NXGL's outlook is uncertain, with significant risks and mixed management priorities. Not investment advice.